Table 1.
Relationship between miR-195-5p and miR-211-5p expression and various clinicopathological variables.
| Variables | miR-195-5p expression | miR-211-5p expression | ||||
|---|---|---|---|---|---|---|
| low | high | p | low | high | p | |
| Total | 31 | 77 | 27 | 79 | ||
| Age | 62.9 ± 10.9 | 62.4 ± 8.9 | 0.783 | 62.6 ± 9.5 | 62.2 ± 9.4 | 0.849 |
| Gender | 0.323 | 0.566 | ||||
| male | 25 (80.6%) | 55 (71.4%) | 19 (70.4%) | 60 (75.9%) | ||
| female | 6 (19.4%) | 22 (28.6%) | 8 (29.6%) | 19 (24.1%) | ||
| Smoking | 0.240 | 0.109 | ||||
| no | 23 (74.2%) | 48 (62.3%) | 21 (77.8%) | 48 (60.8%) | ||
| yes | 8 (25.8%) | 29 (37.7%) | 6 (22.2%) | 31 (39.2%) | ||
| Alcohol abuse | 0.789 | 0.847 | ||||
| no | 23 (74.2%) | 59 (76.6%) | 21 (77.8%) | 60 (75.9%) | ||
| yes | 8 (25.8%) | 18 (23.4%) | 6 (22.2%) | 19 (24.1%) | ||
| Hypertension | 0.570 | 0.038* | ||||
| no | 20 (64.5%) | 54 (70.1%) | 14 (51.9%) | 58 (73.4%) | ||
| yes | 11 (35.5%) | 23 (29.9%) | 13 (48.1%) | 21 (26.6%) | ||
| Diabetes | 0.080 | 0.378 | ||||
| no | 28 (90.3%) | 58 (75.3%) | 23 (85.2%) | 61 (77.2%) | ||
| yes | 3 (9.7%) | 19 (24.7%) | 4 (14.8%) | 18 (22.8%) | ||
| Heart Disease | 0.146 | 0.774 | ||||
| no | 31 (100.0%) | 72 (93.5%) | 26 (96.3%) | 75 (94.9%) | ||
| yes | 0 (0.0%) | 5 (6.5%) | 1 (3.7%) | 4 (5.1%) | ||
| COPD | 0.567 | 0.181 | ||||
| no | 29 (93.5%) | 74 (96.1%) | 27 (100.0%) | 74 (93.7%) | ||
| yes | 2 (6.5%) | 3 (3.9%) | 0 (0.0%) | 5 (6.3%) | ||
| NSAIDS | 0.146 | 0.774 | ||||
| no | 31 (100.0%) | 72 (93.5%) | 26 (96.3%) | 75 (94.9%) | ||
| yes | 0 (0.0%) | 5 (6.5%) | 1 (3.7%) | 4 (5.1%) | ||
| Familial Cancer History | 0.170 | 0.033* | ||||
| no | 28 (90.3%) | 61 (79.2%) | 26 (96.3%) | 62 (78.5%) | ||
| yes | 3 (9.7%) | 16 (20.8%) | 1 (3.7%) | 17 (21.5%) | ||
| Tumor Diameter | 0.476 | 0.653 | ||||
| ≤5cm | 22 (73.3%) | 59 (79.7%) | 22 (81.5%) | 58 (77.3%) | ||
| >5cm | 8 (26.7%) | 15 (20.3%) | 5 (18.5%) | 17 (22.7%) | ||
| Location | 0.778 | 0.451 | ||||
| cardia | 7 (23.3%) | 20 (26.0%) | 5 (19.2%) | 21 (26.6%) | ||
| non-cardia | 23 (76.7%) | 57 (74.0%) | 21 (80.8%) | 58 (73.4%) | ||
| Infiltration Depth | 0.577 | 0.104 | ||||
| T1,T2 | 16 (53.3%) | 35 (47.3%) | 17 (63.0%) | 34 (44.7%) | ||
| T3,T4 | 14 (46.7%) | 39 (52.7%) | 10 (37.0%) | 42 (55.3%) | ||
| Differentiation | 0.385 | 0.082 | ||||
| well | 8 (27.6%) | 15 (19.7%) | 9 (34.6%) | 14 (18.2%) | ||
| poor | 21 (72.4%) | 61 (80.3%) | 17 (65.4%) | 63 (81.8%) | ||
| Lymphovascular Infiltration | 0.497 | 0.967 | ||||
| no | 20 (69.0%) | 47 (61.8%) | 17 (65.4%) | 50 (64.9%) | ||
| yes | 9 (31.0%) | 29 (38.2%) | 9 (34.6%) | 27 (35.1%) | ||
| Lymph Node Metastasis | 0.104 | 0.016* | ||||
| no | 18 (58.1%) | 31 (40.8%) | 18 (66.7%) | 31 (39.7%) | ||
| yes | 13 (41.9%) | 45 (59.2%) | 9 (33.3%) | 47 (60.3%) | ||
| Nerve Invasion | 0.859 | 0.149 | ||||
| no | 17 (58.6%) | 46 (60.5%) | 19 (73.1%) | 44 (57.1%) | ||
| yes | 12 (41.4%) | 30 (39.5%) | 7 (26.9%) | 33 (42.9%) | ||
| Tumor Stage | 0.106 | 0.034* | ||||
| I,II | 21 (67.7%) | 39 (50.6%) | 20 (74.1%) | 40 (50.6%) | ||
| III,IV | 10 (32.3%) | 38 (49.4%) | 7 (25.9%) | 39 (49.4%) | ||
Summary of the baseline information and differences of miR-195-5p and miR-211-5p expression in various clinicopathological characteristics of gastric cancer patients. (* p-value<0.05).